AR110904A1 - ANTICUERPOS ANTI-TGF-b Y SU USO - Google Patents
ANTICUERPOS ANTI-TGF-b Y SU USOInfo
- Publication number
- AR110904A1 AR110904A1 ARP180100118A ARP180100118A AR110904A1 AR 110904 A1 AR110904 A1 AR 110904A1 AR P180100118 A ARP180100118 A AR P180100118A AR P180100118 A ARP180100118 A AR P180100118A AR 110904 A1 AR110904 A1 AR 110904A1
- Authority
- AR
- Argentina
- Prior art keywords
- tgf
- antibody
- seq
- conditions
- antibodies
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La solicitud proporciona un anticuerpo pan-TGF-b mejorado para el tratamiento de afecciones que están mediadas por TGF-b, incluyendo enfermedades autoinmunitarias, afecciones fibróticas, y cánceres. También se proporcionan usos y usos del anticuerpo junto con otros agentes inmunomoduladores tales como un anticuerpo anti-PD-1. Reivindicación 1: Un anticuerpo monoclonal aislado que se une específicamente a TGF-b1, TGF-b2, y TGF-b3 humano, que comprende las regiones determinantes de la complementariedad de cadena pesada (CDR) 1 - 3 de SEQ ID Nº 1 y las CDR1 - 3 de cadena ligera de SEQ ID Nº 2, en donde el anticuerpo comprende una región constante de IgG4 que tiene una prolina en la posición 228 (numeración UE).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448800P | 2017-01-20 | 2017-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110904A1 true AR110904A1 (es) | 2019-05-15 |
Family
ID=66669189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100118A AR110904A1 (es) | 2017-01-20 | 2018-01-18 | ANTICUERPOS ANTI-TGF-b Y SU USO |
Country Status (2)
| Country | Link |
|---|---|
| KR (3) | KR102699080B1 (es) |
| AR (1) | AR110904A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2976359T2 (sl) * | 2013-03-20 | 2022-05-31 | Genzyme Corporation | Postopki zdravljenja imperfektne osteogeneze |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JP6901400B2 (ja) * | 2015-04-03 | 2021-07-14 | ゾーマ テクノロジー リミテッド | ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法 |
-
2018
- 2018-01-18 AR ARP180100118A patent/AR110904A1/es unknown
- 2018-01-19 KR KR1020237027750A patent/KR102699080B1/ko active IP Right Grant
- 2018-01-19 KR KR1020247028042A patent/KR20240133763A/ko active Application Filing
- 2018-01-19 KR KR1020197024043A patent/KR102568885B1/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190105077A (ko) | 2019-09-11 |
| KR20230124768A (ko) | 2023-08-25 |
| KR102568885B1 (ko) | 2023-08-21 |
| KR102699080B1 (ko) | 2024-08-27 |
| KR20240133763A (ko) | 2024-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200734A1 (es) | Anticuerpos anti-tgf-beta y su uso | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| PE20190398A1 (es) | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| EA201991729A1 (ru) | Антитела к tgf-бета и их применение | |
| ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
| PE20200384A1 (es) | Metodo de fabricacion de anticuerpos bispecificos, anticuerpos bispecificos y uso terapeutico de dichos anticuerpos | |
| UY36692A (es) | Anticuerpos anti-cd40 y usos de los mismos | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| PE20211887A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| PE20161389A1 (es) | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda | |
| EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| MX2020008122A (es) | Anticuerpos anti-pd-1. | |
| AR119507A1 (es) | Anticuerpos triespecíficos anti-pd-1 / lag3 / tigit y anticuerpos biespecíficos anti-pd-1 / lag3 | |
| EA201992460A1 (ru) | Антитела-агонисты btla и их применение | |
| CL2022000230A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| BR112022021641A2 (pt) | Tratamento de combinação de anticorpos anti-cd40 para câncer |